Recognised by global pharmaceutical companies, manufacturers and medical device clients for its expertise in investigative matters, Morgan Lewis & Bockius LLP‘s workload also encompasses research, development, regulatory approval, as well as licensing, collaborations and M&A. Ning Zhang divides his time between Hong Kong and Beijing, advising on high-value and complex cross-border transactions involving M&A, private equity and venture capital. Lesli Ligorner sits in the Tokyo and Beijing offices, providing expertise on labour and employment matters, while Shanghai and Boston-based Todd Liao excels in complex financial and commercial transactions. Other key names to note include Hong Kong-based Maurice Hoo and Beijing-based Bingna Guo.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Morgan, Lewis & Bockius possesses broad visibility into both U.S. and local laws. As a partner, they excel at helping us understand common practices rather than simply interpreting regulations. The practical advice they provide is the greatest added value we anticipate.’
‘We greatly appreciate that the team’s lawyers are able to respond to our needs promptly, provide the historical background of legal issues, and maintain consistency in their opinions. We are also very grateful for the team’s legal updates, which allow us to stay informed about market changes in a timely manner.’
Key clients
- CMG-SDIC Capital
- Shanghai Duoning Biotechnology
Work highlights
Advised HongShan Capital, as an existing important shareholder of Cullgen, in Cullgen’s merger transaction with Pulmatrix. MLB reviewed all transaction documents, resolutions and consent and all other relevant documents and assisted with HongShan’s review and sign off on the transaction.
Rpresented Bruker Corporation in its $392.6 million acquisition of NanoString Technologies, Inc., a provider of life science tools for discovery and translational research. NanoString Technologies is a leader in spatial biology, offering an ecosystem of innovative discovery and translational research solutions, empowering its customers to map the universe of biology.
Advised B Capital, a leading global private equity firm with $7+ billion in assets under management, in its investment in and exit from ProfoundBio, a leading clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer. We advised B Capital in a Series A+ investment in, and US$1.8 billion trade sale of ProfoundBio.
Practice head
Ning Zhang; Bingna Guo; K Lesli Ligorner; Maurice Hoo; Todd Liao